India Biotechnology Stock News
Categories
- All
- Editor's Picks
- Stock Market News
- Q&A with Gurus
- Gurus' Stock Picks
- Insider Transaction
- Earning Reports
- CEO Shareholder Letters
- Press Release
- Earnings Call Transcripts
- Instant Alerts
- Podcast
Industries
- Aerospace & Defense
- Agriculture
- Asset Management
- Banks
- Beverages - Alcoholic
- Beverages - Non-Alcoholic
- Biotechnology
- Building Materials
- Business Services
- Capital Markets
- Chemicals
- Conglomerates
- Construction
- Consumer Packaged Goods
- Credit Services
- Diversified Financial Services
- Drug Manufacturers
- Education
- Farm & Heavy Construction Machinery
- Forest Products
- Furnishings, Fixtures & Appliances
- Hardware
- Healthcare Plans
- Healthcare Providers & Services
- Homebuilding & Construction
- Industrial Distribution
- Industrial Products
- Insurance
- Interactive Media
- Manufacturing - Apparel & Accessories
- Media - Diversified
- Medical Devices & Instruments
- Medical Diagnostics & Research
- Medical Distribution
- Metals & Mining
- Oil & Gas
- Other Energy Sources
- Packaging & Containers
- Personal Services
- Real Estate
- REITs
- Restaurants
- Retail - Cyclical
- Retail - Defensive
- Semiconductors
- Software
- Steel
- Telecommunication Services
- Tobacco Products
- Transportation
- Travel & Leisure
- Utilities - Independent Power Producers
- Utilities - Regulated
- Vehicles & Parts
- Waste Management
Biotechnology
Dishman Carbogen Amics Ltd (BOM:540701) Q1 2025 Earnings Call Transcript Highlights: Strong India CRAMS Revenue Growth Amid Global Challenges
Key takeaways include a significant increase in India CRAMS revenue and strategic cost-saving measures, despite deferred orders and a revenue decline in the Dutch entity. Sep 13, 2024
Biotechnology
Dishman Carbogen Amics Ltd (BOM:540701) Q3 2024 Earnings Call Transcript Highlights: Revenue Growth Amidst Profitability Challenges
Dishman Carbogen Amics Ltd (BOM:540701) reports a 2% revenue increase for Q3 FY24, with significant growth in the Carbogen Amcis CRAMS segment. Sep 13, 2024
Biotechnology
Biocon Ltd (BOM:532523) (Q4 2024) Earnings Call Transcript Highlights: Strong Fiscal Year Growth Amidst Quarterly Challenges
Biocon Ltd (BOM:532523) reports a 35% year-on-year revenue growth for FY24, driven by the Biologics segment, despite facing quarterly profit declines and market pressures. Sep 13, 2024
Biotechnology
Syngene International Ltd (BOM:539268) Q1 2025 Earnings Call Transcript Highlights: Navigating Challenges and Seizing Opportunities
Despite a dip in revenue and profit, Syngene International Ltd (BOM:539268) remains optimistic with strong client engagement and future growth prospects. Jul 26, 2024